Project Description

Can-Fite
Can-Fite Inks $42 Million Deal for European Distribution

Date & Time:

March 25, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

Can-Fite BioPharma, an Israel-based drug development company, announced it has signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases.

Piclidenoson is currently in a multinational Phase III study as a treatment for moderate to severe psoriasis. It is a novel, orally bioavailable drug with a favorable therapeutic index and excellent safety profile in Phase II clinical studies.

In addition to liver disease, Piclidenoson has just entered into a Phase II U.S. study for the treatment of moderate to severe COVID-19 due to its anti-inflammatory properties.

Please join us March 25, as Can-Fite CEO, Dr. Pnina Fishman discusses these developments and news about the company’s other programs.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.